Menstrual cycle variation in mammographic breast density: so who cares?

So who cares? Is it really important that there is a 4% excess in the proportion of women with mammographically ‘‘extremely dense breasts’’ in the luteal phase of the menstrual cycle compared with the follicular phase? For that is what White et al. (1) have clearly shown in this issue of the Journal in a study based on an analysis of 2591 menstruating women who had screening mammograms in a health maintenance organization during the last 7 months of 1996. My opinion is that this excess is important. As White et al. (1) point out, increased mammographic density is associated with decreased mammographic sensitivity and decreased mammographic specificity. Both of these operating characteristics put younger women at a disadvantage compared with older women in terms of benefiting from the early detection of breast cancer. As for the small size of the effect (4% overall), it is often overlooked that a small effect on a large population can have an impact far greater than a large effect on a small population. When millions of women are being encouraged to seek mammographic screening in their forties, even a small effect may prove to be important. Women in their forties who undergo mammographic screening are facing high probabilities of false-positive screens, namely, a 30% cumulative risk after five mammograms and a 56% cumulative risk after 10 mammograms (2); however, they achieve only a rather small and delayed benefit in terms of a reduction in breast cancer mortality when they are screened in their forties (3,4). Women surely will welcome any opportunity to enhance mammography’s effectiveness. Follicular timing may appeal to them. White et al. (1) found that body mass index (BMI) had the strongest association with breast density overall. Fifty-three percent of women in the lowest BMI quartile had extremely dense breasts compared with 5% in the upper quartile. However, even after adjustment for BMI, menstrual cycle phase was associated with breast density. When women were stratified by BMI (above and below the median), the association of menstrual phase with density was stronger for women in the lower half (P<.01). The proportions of leaner women with extremely dense breasts in the luteal phase were 46% for week 3 and 45% for week 4, while in the follicular phase, the proportions were 40% for week 1 and 35% for week 2.

[1]  Albert,et al.  THE CHILDREN'S HOSPITAL OF PHILADELPHIA , 1955 .

[2]  Gunnar Eklund,et al.  Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985 .

[3]  J. A. Thomas,et al.  Effects of testosterone and prolactin or growth hormone on the accessory sex organs of castrated mice. , 1975, The Journal of endocrinology.

[4]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[5]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[6]  A. Schally,et al.  Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. , 1997, British Journal of Cancer.

[7]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[8]  J. Veldhuis,et al.  Demonstration of a lack of racial difference in secretion of growth hormone despite a racial difference in bone mineral density in premenopausal women--a Clinical Research Center study. , 1996, The Journal of clinical endocrinology and metabolism.

[9]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[10]  S. Rubin,et al.  Efficacy of screening mammography. A meta-analysis. , 1995, JAMA.

[11]  R. Baxter,et al.  Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia , 1997, Clinical endocrinology.

[12]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[13]  C. Mantzoros,et al.  Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. , 1997, British Journal of Cancer.

[14]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[15]  P. Stricker,et al.  Growth factor involvement in progression of prostate cancer. , 1998, Clinical chemistry.

[16]  R Tibshirani,et al.  Impact of menstrual phase on false‐negative mammograms in the canadian national breast screening study , 1997, Cancer.

[17]  A. Miller,et al.  Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[19]  H. Huynh,et al.  Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. , 1998, Endocrinology.

[20]  R. Rosenfeld,et al.  Assays for insulin-like growth factors and their binding proteins: practicalities and pitfalls. , 1996, The Journal of pediatrics.

[21]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[22]  E White,et al.  Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. , 1998, Journal of the National Cancer Institute.

[23]  P. Carroll,et al.  Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review , 1998 .

[24]  I. Powell,et al.  Prostate cancer and African-American men. , 1997, Oncology.

[25]  P. Marzullo,et al.  Prostatic hyperplasia: an unknown feature of acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[27]  L. Plöen,et al.  Effects of very high doses of human growth hormone (hGH) on the male reproductive system in the dog , 2009, Andrologia.

[28]  D C Slawson,et al.  Efficacy of screening mammography. , 1995, The Journal of family practice.

[29]  J. Yesavage,et al.  Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. , 1998, The Journal of clinical endocrinology and metabolism.

[30]  S. Humphries,et al.  Apal polymorphism in insulin-like growth factor II (IGF2) gene and weight in middle-aged males , 1997, International Journal of Obesity.

[31]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[32]  L. Tabár,et al.  REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985, The Lancet.

[33]  V. Ernster Mammography screening for women aged 40 through 49--a guidelines saga and a clarion call for informed decision making. , 1997, American journal of public health.

[34]  L Nyström,et al.  Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization. , 1997, Journal of the National Cancer Institute. Monographs.